Rathbones Group’s iShares Biotechnology ETF IBB Stock Holding History

Rathbones Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-2,898	Closed	-$332K	–	325
2015 Q1	$332K	Hold	2,898	–	–	0.02%	241
2014 Q4	$293K	Hold	2,898	–	–	0.02%	251
2014 Q3	$264K	Hold	2,898	–	–	0.02%	255
2014 Q2	$248K	Buy	2,898 +198	+7%	+$15.6K	0.02%	255
2014 Q1	$213K	Buy	+2,700	New	+$225K	0.02%	253

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Rathbones Group's IBB Position: Q2 2015 in Review

Rathbones Group sold out of iShares Biotechnology ETF (IBB) in Q2 2015, closing a stake of 2,898 shares — an estimated $332K sold.

Rathbones Group first reported a position in IBB in Q1 2014 and held it in 5 quarters. The position peaked at $332K in Q1 2015. 420 funds tracked by Wall St. Rank hold IBB as of Q2 2015.

Rathbones Group reported no remaining iShares Biotechnology ETF position as of Q2 2015 after selling out during the quarter.
Rathbones Group sold 2,898 iShares Biotechnology ETF shares in Q2 2015, an estimated $332K.
Rathbones Group first reported a position in iShares Biotechnology ETF in Q1 2014 and held it in 5 quarters.
Rathbones Group's iShares Biotechnology ETF position peaked at $332K in Q1 2015.
420 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2015.

Based on Rathbones Group's 13F filing for Q2 2015, filed 5 Aug 2015.